• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4619878)   Today's Articles (229)   Subscriber (49404)
For: Hendrix C. Radiation safety with Yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy. Semin Oncol Nurs 2004;20:14-9. [PMID: 15160857 DOI: 10.1053/j.soncn.2004.02.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Number Cited by Other Article(s)
1
Eskian M, Khorasanizadeh M, Zinzani PL, Rezaei N. Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphoma. Immunotherapy 2018;10:699-711. [DOI: 10.2217/imt-2017-0169] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]  Open
2
Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step. Nucl Med Commun 2009;30:5-15. [DOI: 10.1097/mnm.0b013e328313e565] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
3
Liebenguth P, Vogt Temple S. Radioimmunotherapy for non-Hodgkin's lymphoma. Semin Oncol Nurs 2007;22:257-66. [PMID: 17095402 DOI: 10.1016/j.soncn.2006.07.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA